va-Q-tec expands international capacities with a subsidiary in India
With the new subsidiary, the company is supplementing its international offering with additional local sales and service capacities
va-Q-tec, an innovative solutions company in the insulation industry, expands its global presence by opening an Indian subsidiary in Mumbai. With the new subsidiary, the company is supplementing its international offering with additional local sales and service capacities.
The drugs and vaccines are often temperature-sensitive and consequently solutions are needed to transport the produced pharmaceuticals safely to their destination. This presents a particular challenge given India's sometimes poorly developed logistics infrastructure and varying climate zones. Due to their outstanding passive technology, va-Q-tec's advanced thermal boxes and containers have been recognized for many years in the temperature-controlled supply chain market as a safe, reliable solution ideal for these types of challenges.
India's economy has been growing steadily for many years, but the pharmaceutical industry has disproportionately taken off as it is strongly supported by the government. The country is considered as one of the world's largest producer of pharmaceuticals, including drugs and vaccines, supplying up to 60 per cent of the world's supply. The country's pharmaceutical market grew to $55 billion in 2020, with potential for more and expected growth to $65-70 billion by 2024.
Through the three TempChain Service Centers in Hyderabad and Mumbai, which have been operating there for several years, va-Q-tec's solutions have already been in use by several well-known companies. These products have proven many times that the special technology and the sophisticated services form an important building block for domestic road transports, but also on long-distance transports by air freight.
The new distribution site will further support the growth of this vital industry. For this purpose, va-Q-tec was able to win Ravi Kumar, a proven expert in the pharmaceutical industry. Together with the Indian team, he will cover the entire country in terms of service and consulting and thus provide intensive support for a large number of projects in the Indian market.
"The new subsidiary in Mumbai is a strategically important next step in making vaccine and drug shipments safer, more reliable and more environmentally friendly not only locally, but globally. We are very proud to be able to respond faster and more directly to the requirements of the fast-growing market with a dynamic local team and thus tailor our services even better to customer needs in India. I am particularly pleased that with Ravi Kumar as Managing Director we can offer the concentrated experience of a true industry expert on site!" says Christopher J. Storch, Global Head of Sales, va-Q-tec Group.
Modern pharmaceuticals, such as Corona mRNA vaccines, in most cases require stable temperatures in various ranges between -70°C and +8°C. This is often a major challenge, especially in a country like India, which spans a range of climates from alpine to the humid and hot outdoor temperatures of the tropics. In addition, many regions of the country have poor infrastructure.